TrialInvestigational new drugs2012

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.

Emma K Beardsley et al.PubMed ↗Publisher ↗

No numbers read from the abstract.